Cathy D. Spillane

Dublin, L, Ireland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC.

CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC.

Journal: JTO clinical and research reports
Published: April 05, 2024

P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer.

P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer.

Journal: Pathology, research and practice
Published: November 21, 2023

Ex vivo expansion of circulating tumour cells (CTCs).

Ex vivo expansion of circulating tumour cells (CTCs).

Journal: Scientific reports
Published: May 19, 2022

The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival.

The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival.

Journal: Human cell
Published: April 19, 2022

The induction of a mesenchymal phenotype by platelet cloaking of cancer cells is a universal phenomenon.

The induction of a mesenchymal phenotype by platelet cloaking of cancer cells is a universal phenomenon.

Journal: Translational oncology
Published: September 15, 2021

Circulating tumour cell enumeration does not correlate with Miller-Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy.

Circulating tumour cell enumeration does not correlate with Miller-Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy.

Journal: Breast cancer research and treatment
Published: March 24, 2020

The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.

The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.

Journal: PloS one
Published: October 24, 2019

Too MAD or not MAD enough: The duplicitous role of the spindle assembly checkpoint protein MAD2 in cancer.

Too MAD or not MAD enough: The duplicitous role of the spindle assembly checkpoint protein MAD2 in cancer.

Journal: Cancer letters
Published: July 18, 2019

Suppression of Natural Killer cell NKG2D and CD226 anti-tumour cascades by platelet cloaked cancer cells: Implications for the metastatic cascade.

Suppression of Natural Killer cell NKG2D and CD226 anti-tumour cascades by platelet cloaked cancer cells: Implications for the metastatic cascade.

Journal: PloS one
Published: August 13, 2018

CD10-/ALDH- cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy.

CD10-/ALDH- cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy.

Journal: Cell death & disease
Published: March 16, 2017

MyD88 is an essential component of retinoic acid-induced differentiation in human pluripotent embryonal carcinoma cells.

MyD88 is an essential component of retinoic acid-induced differentiation in human pluripotent embryonal carcinoma cells.

Journal: Cell death and differentiation
Published: January 27, 2017

Altered expression of mir-222 and mir-25 influences diverse gene expression changes in transformed normal and anaplastic thyroid cells, and impacts on MEK and TRAIL protein expression.

Altered expression of mir-222 and mir-25 influences diverse gene expression changes in transformed normal and anaplastic thyroid cells, and impacts on MEK and TRAIL protein expression.

Journal: International journal of molecular medicine
Published: January 09, 2016
Showing 1-12 of 20

Last Updated: 09/26/2026